Plaque Psoriasis Efficacy and Safety With Secukinumab
NCT02409667
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
16487
Enrollment
INDUSTRY
Sponsor class
Conditions
Plaque Psoriasis
Interventions
BIOLOGICAL:
Secukinumab
Sponsor
Novartis Pharmaceuticals